Clinical Trials Archives

Ivermectin Added to University of Minnesota COVID-19 Drug Trial

23/05/2021 No Comments

Leading the national trial is Dr. Carolyn Bramante, a U internal medicine specialist. Emphasizing the importance of this trial, she says, “Not everybody has access to the vaccine, whereas these medications are existing generics, already FDA-approved, that are available in most pharmacies around the world.” Dr. Bramante continued, “If we find evidence of benefit, [the drugs] could be used immediately anywhere.”

The International Ivermectin for Covid Conference: Recent findings from the Israeli trial of ivermectin versus placebo

25/04/2021 No Comments

The International Ivermectin for Covid Conference: Professor Eli Schwartz shares data and conclusions from his Israeli randomised controlled trial of ivermectin in mild to moderate covid-19.

The International Ivermectin for Covid Conference: Evidence from ongoing trials

24/04/2021 No Comments

Medical experts from around the world joined together to present the very latest real world research on repurposing ivermectin that has the ability to transform global efforts to fight the pandemic. Mr. Andrew Bryant provides an overview of ongoing trials and what they may add to the evidence base.

Philippines Launches Major Ivermectin Clinical Trial to Investigate Efficacy During Unprecedented Spike in Cases

21/04/2021 No Comments

With a surge of SARS-CoV-2 infections and a vaccination drive totaling 1.3 million, the nation’s leadership faces an uphill battle when factoring in their total population of 108 million. Hence the growing interest in ivermectin and the request of hospitals for access to the drug for compassionate use.

NIH to Launch Massive ACTIV-6 Phase 3 Clinical Study Investigating Repurposed Drugs & Ivermectin May be on the List

20/04/2021 No Comments

NIH will provide an initial investment of $155 million in funding for the trial. TrialSite picked up inside rumblings that ivermectin will be one of the economical drugs under investigation. While this study is late in the pandemic, nonetheless TrialSite celebrates Collins and team’s movement in this most important of areas. We don’t currently have approved medication to be self-administered by people suffering mild disease at home & reduce the chance of needing hospitalization.

Open Letter by U.S. Doctors: JAMA Anti-Ivermectin Study Is Misleading and Fatally Flawed

14/04/2021 No Comments

The severe weaknesses of this study make it uninformative about whether ivermectin is beneficial in early COVID-19 treatment. Yet, the authors misleadingly conclude that their findings “do not support the use of ivermectin for treatment of mild COVID-19”, as if they had enough quality data to make that case, which they do not.

The Chloroquine Wars Part V – A Closer Look at RCTs Studying Hydroxychloroquine Efficacy

14/03/2021 No Comments

This is now one of the most well-studied treatments in the history of medicine, and the evidence is overwhelming. The chance that these results could occur at random is approximately 1 in 208 quadrillion. That is, p = 0.000000000000048. Having read a few thousand research papers, I have never before seen a p-value this low in the testing of medicine.

The Chloroquine Wars Part III

06/03/2021 No Comments

If the argument rests on “RCTs as the gold standard”, there is little doubt that the evidence dramatically favors using HCQ as a standard early stage therapeutic! But it is reasonable to assess the quality of all the evidence to reach beyond gold for the ultimate and supreme standards of scientific evidence. That too we plan to present in future articles.

Letter to NEJM queries excessive doses of hydroxychloroquine in Covid-19 ‘Recovery’ trial

10/02/2021 No Comments

The dose used in the RECOVERY trial, arouses concern because it may have been a disease-aggravating factor negating the therapeutic effect.

Hydroxychloroquine Not Linked to Longer Heart Rhythm Intervals in Rheumatoid Arthritis or Lupus Patients

06/11/2020 No Comments

Of the whole study group (RA and SLE), 54% used hydroxychloroquine and 44% had QTc lengths of more than 440 milliseconds. They found that the adjusted QTc length among hydroxychloroquine users was comparable to those who did not use the drug.

COVID-19 outpatients – early risk-stratified treatment with zinc plus low dose hydroxychloroquine and azithromycin: a retrospective case series study

26/10/2020 No Comments

This means that zinc, low dose HCQ, and azithromycin and may prevent a large number of hospitalizations and probably deaths during the SARS-CoV-2 pandemic.

COVID-19 mortality risk factors in older people in a long-term care center

02/09/2020 No Comments

It could be possible that this treatment only works when used early and in particular patient groups with similar characteristics as in the present study.

Bring on Britain’s corona clowns: Spectator Australia

20/07/2020 No Comments

Source: Spectator Australia by Rebecca Weisser Big Pharma laughs all the way to the bank The Fawlty Towers episode ’Don’t Mention the War’ has been banned by

The UK medicines agency has given the green light to resume a clinical trial of hydroxychloroquine to prevent Covid-19.

30/06/2020 No Comments

The UK medicines agency has given the green light to resume a clinical trial of hydroxychloroquine to prevent Covid-19.

National Cancer Instititute: List of Active Clinical Trials Using Hydroxychloroquine for Cancer

26/06/2020 No Comments

The clinical trials on this list are studying Hydroxychloroquine. All trials on the list are supported by NCI.

WHO restarts Hydroxychloroquine trials globally after dubious study derailed progress – they’ve confirmed no risk of mortality

04/06/2020 No Comments

On the 25th of May 2020, the World Health Organisation halted hyrdoxychloroquine trials globally within 72 hours of sighting a publication in the Lancet. They

WHO restarts HCQ trial after Lancet concern over paper that trashed it

04/06/2020 No Comments

Source: Indian Express In a statement, The Lancet said that “important scientific questions” were raised about data in the paper authored by cardiologist Mandeep Mehra,

WHO resumes hydroxychloroquine study for Covid-19, after confirming no safety concerns from falsified Lancet study

03/06/2020 No Comments

Source: statnews The World Health Organization is resuming a clinical trial exploring whether the malaria drug hydroxychloroquine can effectively treat Covid-19, after pausing enrollment in

India disagrees with WHO over HCQ assessment – WHO trial dosages four times higher than Indian trials

29/05/2020 No Comments

Source: Zeekannada New Delhi [India], May 29 (ANI): After the Union Health Ministry expressed reservations about the World Health Organisation’s (WHO) advisory to suspend hydroxychloroquine

Australian hydroxychloroquine trials continue as Lancet is questioned over incorrect data

28/05/2020 No Comments

Source: The Guardian Australian researchers query origin of data used for Lancet study. Questions have been raised by Australian infectious disease researchers about a study

Sanford doctor: South Dakota’s hydroxychloroquine study different from others paused

28/05/2020 No Comments

Source: Argus Leader South Dakota’s study of an antimalarial drug’s impact on the coronavirus can’t be compared to other studies halted, a Sanford Health leader said.

Health Canada approves continuation of hydroxychloroquine clinical trials, deplores Lancet study that influenced WHO

28/05/2020 No Comments

Source: Le Devoir Canada Following the publication of the results of a large study indicating that administration of chloroquine or hydroxychloroquine alone or in combination

Nigeria: NAFDAC To Continue Hydroxychloroquine Trial Despite WHO’s Directive

26/05/2020 No Comments

Source: Within Nigeria The National Agency for Food and Drug Administration and Control (NAFDAC) says it will continue hydroxychloroquine clinical trials for COVID-19 treatment despite the suspension

Study: Potential specific therapies in COVID-19 include hydroxychloroquine

21/05/2020 No Comments

Source: SagePub.com Convalescent blood products are promising potential therapies for COVID-19. Other antivirals such as chloroquine or HCQ, remdesivir, and immune modulators such as tocilizumab

50 Science References Supporting Hydroxychloroquine: Microbiology Professor at Universidade de São Paulo, Paola Zanotto

18/05/2020 No Comments

SOURCE: Covexit.com The esteemed professor Paolo Zanotto, from the University of Sao Paulo, has released a list of 50 scientific references supporting the use of

Moderate COVID 19: A First Report on the Pharmacological Outcomes from South Korea

18/05/2020 No Comments

Source: MedRxiv Background: No consensus or evidence-based guideline currently exists for pharmacological therapy against Coronavirus Disease 2019 (COVID 19). While South Korea has been relatively

NIH Launches Clinical Trial to Study Hydroxychloroquine Efficacy in COVID-19

15/05/2020 No Comments

Source: Genetic Engineering & Biotechnology News The lack of treatment options for COVID-19 patients, potential promise in repurposing drugs, and controversy surrounding the anti-malarial drug

Coronavirus: Professor critiques two studies, local AU tests of hydroxychloroquine to go ahead.

08/05/2020 No Comments

Source: The Australian The researchers leading a major Australian clinical trial into whether the drug hydroxychloroquine is effective in treating coronavirus have addressed concerns over

Peer reviewed; 91.7% good outcomes with early treatment of COVID-19 patients using hydroxychloroquine and azithromycin: A retrospective analysis of 1061 cases in Marseille, France

08/05/2020 No Comments

Source: Science Direct Abstract Background In France, the combination hydroxychloroquine (HCQ) and azithromycin (AZ) is used in the treatment of COVID-19. Methods We retrospectively report

VA secretary defends use of hydroxychloroquine, clarifies an analysis led to substantial media misinformation

30/04/2020 No Comments

The records review reported outcomes where hydroxychloroquine alone was provided to our sickest COVID-19 patients. The Veterans who received hydroxychloroquine were at highest risk prior

Iran: Covid-19 Study, a comprehensive investigation from exposure to treatment outcomes – HCQ a treatment option

24/04/2020 No Comments

Source: medRxiv View ORCID Profile Mohammad Ali Ashraf, Nasim Shokouhi, Elham Shirali, Fateme Davari-tanha, Omeed Memar, View ORCID Profile Alireza Kamalipour, Ayein Azarnoush, Avin Mabadi, Adele Ossareh, Milad Sanginabadi, Talat Mokhtari Azad, Leila Aghaghazvini, Sara Ghaderkhani, Tahereh Poordast, Alieh Pourdast, Pershang Nazemi

Tag: Clinical Trials

Copyright 2020 © The Palmer Foundation